Back to News
Market Impact: 0.35
US WorldMeds Acquires Orbus Therapeutics, Expanding Commitment to Rare Diseases and Advancing Eflornithine in Adult Malignant Glioma
Source: PR Newswire
M&A & RestructuringHealthcare & Biotech
The acquisition builds on Phase 3 STELLAR results showing clinically meaningful improvements in overall and progression-free survival among a subgroup of patients with recurrent IDH-mutant Grade 3 astrocytoma. The available article text provides no acquisition terms or numerical effect sizes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- A. O. Smith sells 81% stake in China business to CPE
- Guidewire buys Hyperexponential for $1.7B in cash
- What's behind the AI trade comeback — plus, our take on Intel's latest deal
- Talos Energy 10% owner sells $45.8m in shares
- Visa shares fall as weak 2027 outlook overshadows fourth-quarter earnings beat
- Konecta Gets Lender Forbearance to Negotiate Debt Restructuring